Sharon Mates Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Sharon Mates is Chairman and CEO of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 0 shares of ITCI, which is worth approximately $0. The most recent transaction as insider was on Aug 23, 2024, when has been sold 28,680 shares (Common Stock) at a price of $17.57 per share, resulting in proceeds of $503,907. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Sharon Mates Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 23 2024	BUY Exercise of conversion of derivative security	$503,907 $17.57 p/Share	28,680 Added 2.54%	1,099,009 Common Stock
Aug 22 2024	SELL Open market or private sale	$2,954,681 $75.03 p/Share	39,380 Reduced 3.55%	1,070,329 Common Stock
Aug 22 2024	BUY Exercise of conversion of derivative security	$691,906 $17.57 p/Share	39,380 Added 3.43%	1,109,709 Common Stock
Aug 21 2024	SELL Open market or private sale	$4,066,097 $76.7 p/Share	53,013 Reduced 4.72%	1,070,329 Common Stock
Aug 21 2024	BUY Exercise of conversion of derivative security	$931,438 $17.57 p/Share	53,013 Added 4.51%	1,123,342 Common Stock
Apr 24 2024	BUY Exercise of conversion of derivative security	$344,744 $17.22 p/Share	20,020 Added 1.84%	1,070,329 Common Stock
Mar 11 2024	SELL Open market or private sale	$1,361,608 $66.21 p/Share	20,565 Reduced 1.92%	1,050,309 Common Stock
Mar 10 2024	BUY Exercise of conversion of derivative security	-	20,565 Added 1.88%	1,070,874 Common Stock
Mar 07 2024	SELL Open market or private sale	$2,713,454 $66.65 p/Share	40,712 Reduced 3.73%	1,050,309 Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	-	40,712 Added 3.6%	1,091,021 Common Stock
Feb 26 2024	SELL Open market or private sale	$1,565,938 $69.32 p/Share	22,590 Reduced 2.11%	1,050,309 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	22,590 Added 2.06%	1,072,899 Common Stock
Feb 02 2024	SELL Open market or private sale	$2,272,328 $67.06 p/Share	33,885 Reduced 3.13%	1,050,309 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	33,885 Added 3.03%	1,084,194 Common Stock
Jan 18 2024	SELL Open market or private sale	$4,463,505 $65.72 p/Share	67,917 Reduced 6.07%	1,050,309 Common Stock
Jan 18 2024	BUY Exercise of conversion of derivative security	$1,145,080 $16.86 p/Share	67,917 Added 5.73%	1,118,226 Common Stock
Jan 17 2024	SELL Open market or private sale	$3,189,411 $66.33 p/Share	48,084 Reduced 4.38%	1,050,309 Common Stock
Jan 17 2024	BUY Exercise of conversion of derivative security	$810,696 $16.86 p/Share	48,084 Added 4.19%	1,098,393 Common Stock
Jan 16 2024	SELL Open market or private sale	$5,058,983 $67.13 p/Share	75,361 Reduced 6.69%	1,050,309 Common Stock
Jan 16 2024	BUY Exercise of conversion of derivative security	$1,270,586 $16.86 p/Share	75,361 Added 6.27%	1,125,670 Common Stock
Sep 19 2023	SELL Open market or private sale	$2,405,852 $54.17 p/Share	44,413 Reduced 4.06%	1,050,309 Common Stock
Sep 18 2023	SELL Open market or private sale	$2,987,801 $53.75 p/Share	55,587 Reduced 4.83%	1,094,722 Common Stock
Mar 13 2023	SELL Open market or private sale	$916,582 $44.57 p/Share	20,565 Reduced 1.79%	1,130,309 Common Stock
Mar 13 2023	BUY Exercise of conversion of derivative security	$65,199 $3.26 p/Share	20,000 Added 1.71%	1,150,309 Common Stock
Mar 10 2023	SELL Open market or private sale	$1,791,515 $42.89 p/Share	41,770 Reduced 3.56%	1,130,309 Common Stock

Sharon Mates

Chairman and CEO

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Value

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI

Account